COST EFFECTIVENESS ANALYSIS EVALUATING FACTOR VIII AS PRIMARY PROPHYLAXIS TREATMENT FOR PATIENTS WITH SEVERE HAEMOPHILIA A IN THE NETHERLANDS

被引：0
|
作者：
Kip, M. [1 ]
van den Bosch, M. [2 ,3 ]
Fischer, K. [4 ]
Tamminga, R. [5 ]
Lepage-Nefkens, I [1 ]
机构：
[1] PANAXEA, Enschede, Netherlands
[2] Bayer, Mijdrecht, Netherlands
[3] Univ Med Ctr Utrecht, Van Creveldkliniek, Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[5] Univ Med Ctr Groningen, Beatrix Childrens Hosp, NL-9713 AV Groningen, Netherlands
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1687
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY57
引用
收藏
页码：A531 / A531
页数：1
相关论文
共 50 条
  • [31] Adult severe haemophilia A patients under long-term prophylaxis with factor VIII in routine clinical practice
    Mingot-Castellano, Maria E.
    Gonzalez-Diaz, Laura
    Tamayo-Bermejo, Rocio
    Heiniger-Mazo, Anabel I.
    BLOOD COAGULATION & FIBRINOLYSIS, 2015, 26 (05) : 509 - 514
  • [32] EMICIZUMAB PROPHYLAXIS IN HAEMOPHILIA A PATIENTS WITH INHIBITORS: A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS
    Cortesi, P. A.
    Castaman, G.
    Trifiro, G.
    Ferrario, M.
    Improta, G.
    Mazzaglia, G.
    Molinari, A. C.
    Mantovani, L. G.
    VALUE IN HEALTH, 2019, 22 : S845 - S845
  • [33] CLINICAL RESULTS OF CONTINUOUS PROPHYLAXIS IN PATIENTS WITH SEVERE HAEMOPHILIA AFTER CHANGE IN FACTOR VIII OF EXTENDED AVERAGE LIFESPAN
    Mingot Castellano, M. E.
    Nunez, R.
    Martin, S.
    Entrena Urena, L.
    Fernandez, C.
    Palomo Bravo, A.
    Dominguez, J. F.
    HAEMATOLOGICA, 2019, 104 : 123 - 123
  • [34] A cohort study of the usefulness of primary prophylaxis in patients with severe haemophilia A
    Chiai Nagae
    Atsuki Yamashita
    Tomoko Ashikaga
    Mika Mori
    Mieko Akita
    Kaoru Kitsukawa
    Satoshi Yamazaki
    Kimie Yoshikawa
    Masashi Taki
    International Journal of Hematology, 2016, 104 : 208 - 215
  • [35] Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
    Kragh, Nana
    Tytula, Anna
    Pochopien, Michal
    Aballea, Samuel
    Toumi, Mondher
    Hakimi, Zalmai
    Nazir, Jameel
    Bystricka, Linda
    Fatoye, Francis
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (03) : 262 - 270
  • [36] Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII
    Gelhorn, H.
    Merikle, E.
    Krishnan, S.
    Nemes, L.
    Leissinger, C.
    Valentino, L.
    HAEMOPHILIA, 2013, 19 (01) : 119 - 125
  • [37] Mutational analysis of factor VIII transcripts in haemophilia A patients
    Waseem, NH
    Bagnall, R
    Green, PM
    Giannelli, F
    THROMBOSIS AND HAEMOSTASIS, 1997, : PS929 - PS929
  • [38] COST-UTILITY OF PROPHYLAXIS VS. ON-DEMAND TREATMENT IN SEVERE HAEMOPHILIA A PATIENTS
    Gharibnaseri, Z.
    Davari, M.
    Cheraghali, A.
    Eshghi, P.
    Ravanbod, R.
    Spendar, R.
    Khedmati, J.
    VALUE IN HEALTH, 2016, 19 (07) : A591 - A591
  • [39] BAY 94-9027 PROPHYLAXIS SUSTAINS FACTOR VIII TROUGH LEVELS ABOVE 1% IN ALL TREATMENT REGIMENS IN PATIENTS WITH SEVERE HAEMOPHILIA A FROM PROTECT VIII
    Reding, M. T.
    Mancuso, M. E.
    Poulsen, L. H.
    Enriquez, M. Maas
    Tueckmantel, C.
    Solms, A.
    Holme, P. A.
    HAEMOPHILIA, 2021, 27 : 47 - 47
  • [40] Cost-effectiveness of regular continuous prophylactic treatment in adult patients with severe haemophilia A
    Monzini, M
    Gringeri, A
    Ravera, S
    Mantovani, LG
    VALUE IN HEALTH, 2005, 8 (06) : A125 - A126
12345